Quanterix (QTRX) FDA Approvals $3.28 +0.07 (+2.18%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$3.28 0.00 (0.00%) As of 10/9/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Quanterix's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Quanterix (QTRX). Over the past two years, Quanterix has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Simoa. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Simoa p-Tau 217 FDA Regulatory Events Simoa p-Tau 217 is a drug developed by Quanterix for the following indication: Redefining Alzheimer's Disease Neuropathology Prevalence. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Publication - December 22,2025Publication Drug: Simoa p-Tau 217Announced Date: December 22, 2025Indication: Redefining Alzheimer's Disease Neuropathology PrevalenceAnnouncementQuanterix Corporation announced publication of a landmark study in the prestigious journal Nature.AI SummaryQuanterix Corporation announced publication of a landmark study in Nature that used its ultra‑sensitive Simoa p‑Tau 217 (phosphorylated tau at threonine 217) research assay to perform the largest population‑based assessment of Alzheimer’s disease neuropathology to date. Researchers analyzed more than 11,000 Norwegian adults aged 58 and older and found AD neuropathological change (ADNC) rises sharply with age — about 10% in ages 58–69.9 and 64.9% in those over 90. Among people 70 and older, 30.4% showed ADNC: 11.4% preclinical AD, 10.8% prodromal AD, and 7.4% AD dementia. The study also estimates roughly 10% of the 70+ population meet current treatment eligibility and links AD pathology to sex, APOE genotype, and education. The findings relied on a validated commercial p‑Tau 217 kit (ALZpath p‑Tau‑217 Advantage PLUS) run on a fully automated HD‑X analyzer. Quanterix says its Simoa platform enabled scalable, sensitive blood measurements that make population‑level screening and planning for treatments and trials more feasible.Read Announcement Quanterix FDA Events - Frequently Asked Questions Has Quanterix received FDA approval? As of now, Quanterix (QTRX) has not received any FDA approvals for its therapy in the last two years. What drugs has Quanterix submitted to the FDA? In the past two years, Quanterix (QTRX) has reported FDA regulatory activity for Simoa p-Tau 217. What is the most recent FDA event for Quanterix? The most recent FDA-related event for Quanterix occurred on December 22, 2025, involving Simoa p-Tau 217. The update was categorized as "Publication," with the company reporting: "Quanterix Corporation announced publication of a landmark study in the prestigious journal Nature." What conditions do Quanterix's current drugs treat? Currently, Quanterix has one therapy (Simoa p-Tau 217) targeting the following condition: Redefining Alzheimer's Disease Neuropathology Prevalence. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Alumis FDA EventsArcutis Biotherapeutics FDA EventsBioMarin Pharmaceutical FDA EventsHCW Biologics FDA EventsMilestone Pharmaceuticals FDA EventsPureTech Health FDA EventsGlaukos FDA EventsJohnson & Johnson FDA EventsEli Lilly and Company FDA EventsTeva Pharmaceutical Industries FDA EventsAddex Therapeutics FDA EventsAclarion FDA EventsAgomAb Therapeutics FDA EventsCRISPR Therapeutics FDA EventsDare Bioscience FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies VivoSim Labs FDA Events Agilent Technologies FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:QTRX last updated on 12/22/2025 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...Eagle Publishing | SponsoredThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredTech expert smashes iPhone with golf clubTwenty years ago, Josh Baylin told Congress the iPhone was coming, three years before it launched. A $1,500 be...Stansberry Research | SponsoredElon’s Hiding a Potential $20 Trillion Monster Inside TeslaElon Musk says there is a product inside Tesla's factories he calls the biggest ever made, ten times bigger th...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quanterix Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Quanterix With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Publication - December 22,2025Publication Drug: Simoa p-Tau 217Announced Date: December 22, 2025Indication: Redefining Alzheimer's Disease Neuropathology PrevalenceAnnouncementQuanterix Corporation announced publication of a landmark study in the prestigious journal Nature.AI SummaryQuanterix Corporation announced publication of a landmark study in Nature that used its ultra‑sensitive Simoa p‑Tau 217 (phosphorylated tau at threonine 217) research assay to perform the largest population‑based assessment of Alzheimer’s disease neuropathology to date. Researchers analyzed more than 11,000 Norwegian adults aged 58 and older and found AD neuropathological change (ADNC) rises sharply with age — about 10% in ages 58–69.9 and 64.9% in those over 90. Among people 70 and older, 30.4% showed ADNC: 11.4% preclinical AD, 10.8% prodromal AD, and 7.4% AD dementia. The study also estimates roughly 10% of the 70+ population meet current treatment eligibility and links AD pathology to sex, APOE genotype, and education. The findings relied on a validated commercial p‑Tau 217 kit (ALZpath p‑Tau‑217 Advantage PLUS) run on a fully automated HD‑X analyzer. Quanterix says its Simoa platform enabled scalable, sensitive blood measurements that make population‑level screening and planning for treatments and trials more feasible.Read Announcement
